adeno associated viral vectors market growth, adeno associated viral vectors market scope, adeno associated viral vectors market size, aav vectors market, adeno associated viral vectors market share, adeno associated viral vectors market forecast
What is the present valuation and projected CAGR of the adeno-associated viral vectors market?
The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.69 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to vaccine development, increased funding and investment, academic and industrial collaborations, expansion of clinical trials, and public awareness and advocacy.
The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expanding therapeutic applications, increasing the prevalence of genetic disorders, and neurological disorders, regulatory approvals and support, and cost reductions in production. Major trends in the forecast period include gene therapy advancements, technological innovations, scalable manufacturing processes, collaborations and investments, and technological advancements.
Get Your Free Sample of The Global Adeno-Associated Viral Vectors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp
What key drivers have fueled the adeno-associated viral vectors market’s development over the years?
The increasing prevalence of genetic disorders is expected to propel the growth of the adeno-associated viral vectors market going forward. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, leading to physical or developmental abnormalities. The improved diagnostic techniques, greater awareness, and higher reproductive age, along with environmental factors and genetic drift are leading to the rise in the prevalence of genetic disorders. Adeno-associated viral vectors are utilized in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat conditions like muscular dystrophy or cystic fibrosis. For instance, in February 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital diseases caused an estimated 240,000 baby deaths globally within 28 days of birth each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases. Therefore, the increasing prevalence of genetic disorders is driving the adeno-associated viral vectors market.
What is the segmentation for the adeno-associated viral vectors market?
The adeno-associated viral vectors market covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia
2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy
Order your report now for swift delivery
Who are the most influential companies in the adeno-associated viral vectors market?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics
What are the top industry trends projected to impact the adeno-associated viral vectors market?
Major companies operating in the adeno-associated viral vectors market are focusing on offering off-the-shelf availability of replication-capsid plasmid to gain a competitive edge in the market. Rep/Cap plasmids, commonly utilized in gene therapy for adeno-associated virus (AAV) vector production, are readily available from numerous commercial suppliers catering to molecular biology research needs. For instance, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced off-the-shelf replication-capsid plasmid range streamlines AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, cutting manufacturing efforts by as much as 66%. These ready-to-use plasmids undergo batch production with meticulous documentation, adhering to CMC guidelines and accompanied by Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.
What are the major regional insights for the adeno-associated viral vectors market, and which region holds the top position?
North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Adeno-Associated Viral Vectors Market Report 2025 Offer?
The adeno-associated viral vectors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses commonly used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. AAV’s safety profile and ability to efficiently infect both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
